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BACKGROUND: Many studies have examined the short-term value of high-risk human papillomavirus (hrHPV) testing in predicting
cumulative risk of cervical intraepithelial neoplasia grade 3 or cancer (CIN3þ ). This study focuses on long-term CIN3þ risk after
initial wait and see policy.
METHODS: A total of 342 women with abnormal cytology of borderline/mild dyskaryosis (BMD) or worse (4BMD), included between
1990 and 1992, were followed-up by cytology and hrHPV testing until 1996 and monitored by cytology thereafter. Primary endpoint
was cumulative CIN3þ risk by December 2009.
RESULTS:Women with BMD had a 5-year CIN3þ risk of 22.5% (95% confidence interval (CI) 17.0–29.1) and of 0.7% (0.1–4.5) in the
subsequent 5 years. High-risk human papillomavirus-negative women with BMD had a 5-year risk ofo0.01% (95% CI 0.0–5.1) and
of o0.01% (0.0–5.7) in the following 5 years, while for hrHPV-positive women these risks were 37.5% (29.0–46.9) and 1.6%
(0.2–9.5), respectively. Women with 4BMD had a 5-year risk of 45.1% (36.4–54.1) and of 3.5% (0.9–12.2) in the subsequent 5
years. High-risk human papillomavirus-negative women with 4BMD had a 5-year risk of 7.3% (2.0–23.6) and hrHPV-positive
women of 56.6% (46.4–66.3).
CONCLUSION: Women with BMD have an elevated CIN3þ risk for 5 years only; afterwards their risk is similar to the general
population. High-risk human papillomavirus-negative women with BMD may return to regular screening directly. All other women
with XBMD should be referred for additional testing and/or colposcopy.
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The incidence of cervical cancer has been lowered by the
implementation of population-based screening programmes in
which women are screened by cytological testing (Gustafsson et al,
1997; van Ballegooijen and Hermens, 2000; Castle et al, 2007).
However, the sensitivity of cytological testing for cervical
intraepithelial neoplasia grade 3 or cervical cancer (CIN3þ ) is
moderate and compensated for by repetitive screening (Manos
et al, 1999; Arbyn et al, 2006). In the Netherlands, an abnormal
cytological test result is detected inB2–4% of all screened women
(van Ballegooijen and Hermens, 2000; Bulk et al, 2004; Bulkmans
et al, 2004). In most developed countries, women with minor
cellular abnormalities of borderline and mild dyskaryosis (BMD)
will be followed by cytology, and will be referred for colposcopy if
the smear remains abnormal (van Ballegooijen and Hermens,
2000; Bulkmans et al, 2004, 2007). Women with moderate and
severe abnormalities (4BMD) are referred for colposcopy
(van Ballegooijen and Hermens, 2000; Bulkmans et al, 2004).
However, a substantial proportion of women with abnormal
cytology will regress or do not harbour clinically meaningful
cervical disease and will therefore be unnecessarily retested or
referred.
Infection with a high-risk type of human papillomavirus
(hrHPV) is the causative agent in cervical cancer (Walboomers
et al, 1999; Bosch et al, 2002). Molecular testing for hrHPV has a
higher sensitivity than cytology to detect CIN3þ (Manos et al,
1999; Cuzick et al, 2003, 2008; Arbyn et al, 2004, 2006; Bulkmans
et al, 2007; Mayrand et al, 2007). In women with abnormal
cytology, studies focus on the additional value of hrHPV in
triaging women with equivocal or mildly abnormal cytological test
results in order to increase efficiency of patient management (i.e.,
referral for colposcopy) and to identify women with an increased
risk for high-grade CIN. As most of these studies had a restricted
follow-up of at maximum 6 years, little is known on risk profiles
with longer periods of follow-up and the effect of hrHPV testing in
those situations (Manos et al, 1999; Nobbenhuis et al, 1999; Cuzick
et al, 2003; Arbyn et al, 2004; Bais et al, 2005; Bulk et al, 2007;
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Safaeian et al, 2007; Castle et al, 2009; Rijkaart et al, 2009; Cotton
et al, 2010; Katki et al, 2011; Kelly et al, 2011; Kitchener et al, 2011;
Levi et al, 2011). Only few studies have reported about a follow-up
period of over 10 years (Sherman et al, 2003; Khan et al, 2005;
Schiffman et al, 2011).
In this study we followed a group of women who were diagnosed
with an abnormal cytology result of XBMD for a maximum of
19 years and evaluated their long-term cumulative risk of
developing CIN3þ . Also the value of hrHPV testing for risk
assessment was established as well as the duration of follow-up
needed for women with dyskaryosis.
MATERIALS AND METHODS
Study population
For this cohort study we followed-up women who had participated
in a previous study that studied the association between the
presence of hrHPV and the development of high-grade cervical
lesions (Nobbenhuis et al, 1999). Detailed methods of recruitment
and follow-up until 33 months after intake have been published
previously (Nobbenhuis et al, 1999, 2001). In short, between
June 1990 and December 1992, 353 women were referred to the
colposcopic outpatient clinic (VU University medical centre,
Amsterdam, The Netherlands) with an abnormal cervical cytology
result of mild, moderate or severe dyskaryosis. Until December
1996 each participant had been monitored for cervical disease
every 3–4 months by testing for hrHPV, cytology, and colposcopy.
Three expert colposcopists assessed serial colpophotographs
and gave a consensus impression of the lesion. Only when they
suspected a CIN3 lesion covering three or more cervical quadrants,
or when a cervical smear result suspect of cervical cancer was
found, a biopsy had been taken. At the end of the study in
December 1996, all women had a colposcopic examination
with mandatory biopsy (median 36 months, range 1–75). Women
identified with high-grade disease (CIN2þ ) were treated
according to Dutch guidelines. In Figure 1 follow-up procedures
are depicted in a flowchart.
Procedures
Cytology results were originally reported using a classification that
predated the currently used classification; therefore, all cytological
referral slides were retrieved from the archives for blind review by
an expert gynaeco-pathologist (FvK). Dotted slides were scored
and dichotomised into (p) BMD, or4BMD. Women of whom no
referral slide could be retrieved were excluded from this study.
Between December 1996 and December 2009 all women were
monitored by cytological population-based screening once every
5 years. Interim-colposcopies were performed according to the
national guidelines (NVOG, 2004). To complete the data obtained
from routine screening, we invited all women to visit the
outpatient clinic (VU University medical centre) for additional
cytology and hrHPV testing during 2009 (Figure 1). If travel
distance was a limitation to participate, women were offered the
possibility of performing a hrHPV test at home by self-sampling.
These test results are similar to those acquired by a physician
(Bais et al, 2007; Petignat et al, 2007). Women who had had a
hysterectomy were censored at the date of hysterectomy.
Two cervical specimens were obtained from women who visited
the outpatient clinic (Cervex-brush, Rovers Medical Devices, Oss,
The Netherlands). The first specimen was collected in a liquid-
based cytology medium (Surepath, Tripath Imaging, Burlington
NC, USA), cytologically examined, and classified according
to the CISOE-A classification, which is easily translatable into
the Bethesda 2001 classification (Bulk et al, 2004). The second
specimen was stored in Universal Collection Medium (Qiagen
Corporation, Gaithersburg, MD, USA) for hrHPV testing. Women
who self-sampled returned their cervicovaginal specimen for
hrHPV testing by mail. All hrHPV samples were tested with the
clinically validated GP5þ /6þ PCR with enzyme-immunoassay
read-out using a cocktail probe for 14 hrHPV types (16, 18, 31, 33,
35, 39, 45, 51, 52, 56, 58, 59, 66 and 68), according to established
protocols (van den Brule et al, 2002; Snijders et al, 2005). The PCR
products of hrHPV-positive women were subsequently genotyped
by reverse line blot hybridisation. Samples that were negative for
any specific probe in this reverse hybridisation assay were
considered positive for uncharacterised subtypes or variants
(HPV X).
A standard colposcopic assessment was performed when a
cytological test was abnormal at the threshold of borderline
dyskaryosis, or when the hrHPV test was positive (Figure 1).
Biopsies were taken of all suspect lesions. Histological specimens
were graded as CIN0 (no dysplasia), CIN1, CIN2, CIN3,
adenocarcinoma in situ (AIS) or invasive cancer (Wright, 1995)
and classified according to the highest abnormality found in
biopsy or treatment specimen. Women who developed CIN2þ
were treated according to present guidelines but were censored
at the time of treatment.
In December 2009, the hospital database and the Netherlands
nationwide network and registry of histopathology and cytopathol-
ogy (PALGA; Bunnik, The Netherlands) were reviewed for all
women, irrespective of attendance, to ascertain details of any
additional relevant events and procedures. Ethical approval was
obtained from the Ethics Board of the VU University medical centre.
All women who attended the outpatient clinic or participated by
self-sampling provided additional signed informed consent. The
study is registered in the Dutch trial register (NTR1470).
Statistical methods
In order to report long-term CIN risks in women with dyskaryosis,
this study was designed as a follow-up of an observational cohort
(Nobbenhuis et al, 1999).
As the original study was designed such that no interference
with natural history would occur; a biopsy had only been taken
when a colposcopic impression of CIN3 covering three or more
cervical quadrants was present, or when a cytology result was
suspect of cancer. As a consequence, the exact time at which
CIN3þ lesions had developed was difficult to assess. We have
calculated the 5-year, 10-year and overall risks until detection
of CIN3þ using different approaches. In the first approach, we
equalled the event time to the time of the first abnormal cytological
result of moderate dyskaryosis or worse. In the second approach,
the event time was equalled to the time of histological diagnosis.
As the difference between the risks of these approaches were
minimal (data not shown), we applied the second approach in
further analyses. In women without an event, data were right-
censored at the date of the last registered test.
The primary endpoint was the cumulative risk of CIN3þ .
We repeated the calculations with CIN2þ as secondary endpoint
because treatment of CIN2 is common practice in most western
countries. Both CIN3þ and CIN2þ included cases of AIS,
adenocarcinoma (AC) and squamous cell carcinoma (SCC).
The cumulative CIN3þ risk was estimated by Kaplan–Meier
analysis for the total group as well as for subgroups of different
cytological and hrHPV test results at time of referral. In addition
we repeated the calculations after dichotomising in younger (o30
years) and older (X30 years) women. Differences in cumulative
risk curves between subgroups were assessed by log-rank tests.
For women who did not develop high-grade CIN within
6 months after inclusion, we reset the time at 6 months to 0 to
estimate the value of retesting with cytology, hrHPV or both after 6
months and the risk of persistent hrHPV infection (log-rank tests).
For women who had not developed high-grade CIN at 5 years after
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inclusion, time was reset from 5 years to 0 to estimate the CIN3þ
risk from 5 years onwards.
By Cox regression we calculated CIN hazard ratios and 95%
confidence intervals (CIs) to compare different test result
combinations. Overall cumulative risks were calculated for
different hrHPV genotypes to determine whether genotyping has
additional value in the follow-up of women with abnormal
cytology, focusing on HPV16. All calculations were performed
using SPSS (Version 17.0, SPSS Inc, Chicago, IL, USA). All tests
were two-sided and the level of significance was set at 0.05.
RESULTS
Of the original 353 women, 11 (3.1%) were excluded as no referral
slide could be retrieved for review. For the remaining 342 women
(median age 31 years, range 17–54) maximum follow-up depended
on accrual date and ranged from 17.0 to 19.5 years. The total number
of women years in our study was 3152. Overall censoring percentages
were 13.2% (45 out of 342) at 5 years, 21.6% (74 out of 342) at
10 years and 36.5% (125 out of 342) at 15 years after detection of an
abnormal cytological test result. During follow-up 4 women died of
unrelated disease, 6 moved abroad, and 23 had a hysterectomy. None
of the women had received prophylactic hrHPV vaccination.
During follow-up 105 (30.7%) CIN3þ cases were identified.
Three were invasive cancers, of which two were SCC and one AC;
two were AIS and 100 CIN3. Cervical intraepithelial neoplasia
grade 2 was diagnosed in another 36 women. The cumulative risk
curve of developing CIN3þ after an abnormal cytological test
result in our cohort is shown in Figure 2. The 5-year CIN3þ risk
was 31.1% (95% CI 26.1–36.6) and the risk in the next 5 years
was 1.6% (0.5–4.9). Of all CIN3þ , 96.2% (101 out of 105) were
detected within 5 years of follow-up.
1990-1992 
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1996 
Exit test trial 
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Every  
5 years 
 
 
 
 
2009 
CIN-0/1 
Inclusion 353 women with BMD 
Cytology in population based screening1
All participants: 
Exit colposcopy with mandatory biopsy 
If 
 (a) Cytology suspect of  
microinvasive carcinoma OR 
(b) Colposcopic impression of  
CIN3 in  3 quadrants 
 
hrHPV-testing, Cytology, Colposcopy 
Biopsy CIN2/3  Treatment 
Yes 
No 
Biopsy CIN2/3  Treatment 
CIN-0/1 
No 
Treatment 
CIN 0/1 
Cytology in population based screening1 
All participants: 
hrHPV testing, Cytology 
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b- Colposcopic impression of  
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Review of  
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Figure 1 Flowchart of follow-up procedures. 1 Referral for colposcopy when once a cytology result of4BMD or when twice a result of BMD is detected.
Abbreviations: BMD, borderline or mild dyskaryosis; hrHPV, high-risk human papillomavirus; CIN, cervical intraepithelial neoplasia.
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Table 1 shows the 5- and 10-year risks of developing CIN3þ in
227 hrHPV-positive women (66.4%) and 115 hrHPV-negative
women (33.6%). Only 3 (2.9%) of 105 CIN3þ lesions were found
in women who were hrHPV negative at baseline. These were all
CIN3 lesions. High-risk human papillomavirus-negative women
had a 5-year CIN3þ risk of 1.9% (95% CI 0.5–7.0) and a risk of
1.1% (0.2–6.4) in the next 5 years. These risks were 45.1% (95%
CI 38.4–52.0) and 2.1% (0.5–7.8), respectively, in hrHPV-positive
women. Of the hrHPV-positive women 84.6% (192 out of 227) were
infected with a single hrHPV type, 31 (13.7%) had a double
infection and four (1.8%) were infected with three or more hrHPV
types. All women who developed AIS or invasive cancer had only
one hrHPV type: both SCC and one AIS contained HPV16, the AC
harboured HPV18, and one AIS was positive for HPV45. In 93.3%
(98 out of 105) of CIN3þ cases, the same hrHPV type was present
both in the lesion and at the baseline, including both AIS, the
AC and one SCC. Of one SCC, no hrHPV typing information
was available.
The most prevalent type was HPV16 (105 out of 227, 46.3%),
followed by HPV31 (29 out of 227, 12.8%), HPV18 (22 out of 227,
9.7%) and HPV33 (18 out of 227, 7.9%). The CIN3þ risk of
women infected with HPV16 was higher than that of women
infected with other hrHPV types (Wald-statistic 6.85, P¼ 0.009).
The 5-year risk in HPV16-positive women was 56.5% (95% CI
46.5–66.0) and this was 36.5% (27.9–46.1) in nonHPV16-positive
women. The risks in the subsequent 5 years were 0.01% (95%
CI 0.0–10.7) and 3.4% (0.8–12.2), respectively. After stratification
in two age categories, we found that in younger women (o30
years), HPV16-positive women had a significantly higher CIN3þ
risk than nonHPV16-positive women (Wald statistic 13.01,
P¼ 0.003, Table 1). Their 5-year CIN3þ risks were 61.5% (95%
CI 46.8–74.4) and 19.9% (10.6–34.3), respectively. In older women
(X30 years), we found no difference in CIN3þ risk between
HPV16-positive women and nonHPV16-positive women (Wald
statistic 0.08, P¼ 0.78). Their respective 5-year risks were 52.1%
(95% CI 38.9–65.1) and 51.1% (39.1–63.0).
In women infected with hrHPV types other than HPV16, 18, 31,
33 and/or 45, the CIN3þ risk remained 24.4% (95% CI 14.7–37.7)
in the first 5 years and was 2.9% (0.5–15.1) in the following
5 years. These risks were similar for both the age categories.
Women with transient hrHPV infections had a lower CIN3þ
risk than women who had a persistent 6-month hrHPV infection
(Wald-statistic 17.3; P¼ 0.0003). The 5-year CIN3þ risk was 2.2%
(95% CI 0.4–12.2) in women who cleared their infection and 56.0%
(48.0–63.7) in women with a persistent infection. Within the
Table 1 Value of hrHPV testing during the follow-up of women with abnormal baseline cytology; 5-year and 10-year risks
CIN3+ CIN2+
Risk 5 Year Risk 10 Year Risk 5 Year Risk 10 Year
Baseline At risk (%) 95% CI (%) 95% CI (%) 95% CI (%) 95% CI
All women 342 31.1 26.1–36.6 32.2 26.9–38.0 38.7 33.6–44.1 41.6 36.2–47.2
HPV negative 115 1.9 0.5–7.0 3.0 0.9–9.2 11.8 7.0–19.2 14.7 9.0–23.1
HPV positive 227 45.1 38.4–52.0 47.0 39.9–54.2 52.3 45.7–58.8 55.2 48.4–61.8
HPV16 105 56.5 46.5–66.0 56.5 46.1–66.3 60.0 50.2–69.1 61.1 51.0–70.3
NonHPV16 122 36.5 27.9–46.1 38.7 29.5–48.8 45.7 37.0–54.7 50.2 41.0–59.3
NonHPV16, 18, 31, 33, 45 61 24.4 14.7–37.7 26.6 16.1–40.6 36.4 25.3–49.2 41.8 29.9–54.7
Age o 30 years
HPV positive 104 40.4 30.7–51.0 41.8 31.6–52.8 49.5 39.8–59.3 54.0 43.9–63.8
HPV16 49 61.5 46.8–74.4 61.5 46.2–74.8 65.8 51.4–77.8 58.1 43.5–71.4
NonHPV16 55 19.9 10.6–34.3 22.8 12.3–38.3 35.2 23.6–48.9 41.5 28.8–55.4
Age X30 years
HPV positive 123 51.5 42.5–60.4 51.5 42.1–60.8 55.5 46.6–64.1 56.4 47.2–65.2
HPV16 56 52.1 38.9–65.1 52.1 38.3–65.5 55.2 42.0–67.7 55.2 41.5–68.1
NonHPV16 67 51.1 39.1–63.0 51.1 38.5–63.6 55.7 43.8–67.0 57.3 44.9–68.8
Clearance o6 monthsa 50 2.2 0.4–12.2 2.2 0.3–13.1 14.6 7.2–27.3 14.6 7.0–28.0
6-Month persistencea 166 56.0 45.0–63.7 57.5 49.2–65.4 61.0 53.2–68.2 64.4 56.5–71.6
Persistence HPV16 77 67.2 55.8–76.9 67.2 55.4–77.2 68.4 57.1–77.9 69.9 58.4–79.4
Persistence nonHPV16 89 45.8 35.1–56.9 48.9 37.6–60.4 54.7 44.1–64.9 59.8 48.9–69.8
Abbreviations: CIN3+¼ cervical intraepithelial neoplasia grade 3 and cancer; CIN2+¼ cervical intraepithelial neoplasia grade 2, 3 and cancer; 95% CI¼ 95% confidence interval;
hrHPV¼ high-risk human papillomavirus. aAll hrHPV-negative women at baseline and all women with a follow-up ofo6 months were excluded. 6-Month persistence: at baseline
and at 6 months at least one detected hrHPV type is similar. Time to event is set equal to histological diagnosis of CIN3+ or CIN2+ lesion.
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Figure 2 Cumulative risk curve of CIN3þ in 342 women
with abnormal cytology (mild to severe dyskaryosis) at baseline.
Abbreviation: CIN3þ , Cervical intraepithelial neoplasia grade 3 or cancer.
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persistent group, the risk of developing CIN3þ was higher in
women positive for HPV16 (67.2%, 95% CI 55.8–76.9) than in
women in whom other hrHPV types persisted (45.8%, 35.1–56.9,
Wald-statistic 4.73; P¼ 0.03).
Women were divided into two groups according to referral
cytology; 210 (61.4%) women had a smear of BMD and 132 (38.6%)
a smear of4BMD. In both these groups the median of cytological
screens between 1996 and 2009 was 3.0 (range 1–9; P¼ 0.71,
Mann–Whitney).
Borderline and mild dyskaryosis
Forty-seven of 210 (22.4%) women with BMD developed CIN3þ .
Their 5-year CIN3þ risk was 22.5% (95% CI 17.0–29.1) and their
risk in the subsequent 5 years was 0.7% (0.1–4.5; Table 2A).
Immediate hrHPV testing clearly stratified these women with
regard to cumulative risk (Wald-statistic 11.08, P¼ 0.001,
Figure 3A). A negative hrHPV test result, present in 84
(40.0%) women, reduced the 5-year CIN3þ risk to 0.01%
Table 2 Risk (%) of cytology and hrHPV testing at baseline and at 6-month follow-up, stratified according to baseline cytology in BMD and 4BMD
(A) Women with borderline and mild dyskaryosis
CIN3+ CIN2+
BMD Risk 5 Year Risk 10 Year Risk 5 Year Risk 10 Year
Baseline Follow-up (6 months)a At risk (%) 95%CI (%) 95%CI (%) 95%CI (%) 95%CI
All 210 22.5 17.0–29.1 23.1 17.4–30.4 31.0 25.0–37.8 33.0 26.6–40.1
Cytology negativeb,c 65 4.9 1.6–13.8 4.9 1.6–14.3 12.5 6.4–22.9 12.5 6.3–23.4
Cytology positiveb,d 127 30.9 23.0–40.1 31.8 23.3–41.7 38.0 29.7–47.0 41.5 32.7–50.9
HPV negative 84 0.0 0.0–5.1 0.0 0.0–5.7 9.9 5.1–18.5 11.2 5.8–20.5
Cytology negativeb 37 0.0 0.0–10.2 0.0 0.0–10.7 5.5 1.5–18.1 5.5 1.5–18.6
Cytology positiveb 40 0.0 0.0–10.7 0.0 0.0–12.5 10.9 4.3–25.1 13.7 5.7–29.5
HPV negative 70 0.0 0.0–6.1 0.0 0.0–6.6 10.4 5.1–20.1 10.4 5.1–20.5
HPV positive 9 0.0 0.0–35.4 0.0 0.0–43.4 12.5 2.2–47.1 25.0 6.6–61.1
Double negative 36 0.0 0.0–10.4 0.0 0.0–11.0 5.6 1.5–18.5 5.6 1.5–19.0
Cytology and/or HPV positive 48 0.0 0.0–9.2 0.0 0.0–10.4 13.4 6.2–26.4 15.7 7.5–30.1
HPV positivec,d 126 37.5 29.0–46.9 38.5 29.5–48.4 44.9 37.1–52.9 47.6 38.5–56.9
Cytology negativeb 28 11.6 3.9–29.9 11.6 3.6–31.5 22.0 10.5–40.5 22.0 10.0–41.7
Cytology positivec,d 87 44.9 34.2–56.1 46.3 35.0–57.9 50.3 39.6–60.9 54.2 43.1–64.9
HPV negative 29 0.0 0.0–13.8 0.0 0.0–15.5 11.0 3.8–27.9 11.0 3.6–29.2
HPV positivec,d 91 46.3 35.8–57.1 47.6 36.5–59.0 52.2 41.8–62.4 55.9 45.0–66.3
Double negative 15 0.0 0.0–22.8 0.0 0.0–25.9 6.7 1.1–30.9 6.7 1.0–33.4
Cytology and/or HPV positivec,d 105 40.6 31.1–50.9 41.2 31.1–52.0 47.4 37.8–57.1 50.6 40.6–60.6
HPV16 55 49.8 36.2–63.4 49.8 35.6–64.0 55.3 41.8–68.1 57.4 43.4–70.3
nonHPV16 71 29.8 18.4–40.2 29.8 19.3–43.0 38.7 28.1–50.5 40.3 29.0–52.7
(B) Women with moderate and severe dyskaryosis
CIN3+ CIN2+
4BMD Risk 5 Year Risk 10 Year Risk 5 Year Risk 10 Year
Baseline Follow-up (6 months)a At risk (%) 95%CI (%) 95%CI (%) 95%CI (%) 95%CI
All 132 45.1 36.4–54.1 47.0 37.8–56.4 51.2 42.6–59.7 55.3 46.4–63.9
Cytology negativeb 21 5.0 0.9–23.6 15.0 5.1–36.7 5.0 0.9–23.6 15.0 5.1–36.7
Cytology positiveb 98 53.9 43.5–64.0 53.9 42.9–64.5 60.7 50.7–69.9 64.0 53.7–73.2
HPV negative 31 7.3 2.0–23.6 11.2 3.4–31.0 16.9 7.4–34.2 24.2 11.6–43.6
Cytology negativeb 10 0.0 0.0–29.9 11.1 1.8–45.6 0.0 0.0–29.9 11.1 1.8–45.6
Cytology positiveb 18 13.5 3.7–39.1 13.5 3.0–44.3 29.4 13.3–53.1 36.5 16.9–61.9
HPV negative 30 7.4 2.0–23.8 11.3 3.5–31.1 14.1 5.6–31.3 21.6 9.7–41.3
HPV positive 1 0.0 - 0.0 - 100 20.7–100 100 20.7–100
Double negative 10 0.0 0.0–29.9 11.1 1.8–45.6 0.0 0.0–29.9 11.1 1.8–45.6
Cytology and/or HPV positive 21 11.2 3.0–33.7 11.2 2.6–37.5 25.0 11.2–46.9 30.8 14.2–54.5
HPV positivee 101 56.6 46.4–66.3 57.8 47.2–67.7 61.4 51.5–70.4 64.6 54.6–73.5
Cytology negativeb 11 9.1 1.6–37.8 18.2 5.1–47.7 9.1 1.6–37.8 18.2 5.1–47.7
Cytology positiveb,e 82 62.2 50.7–72.4 62.2 50.3–72.8 67.3 56.4–76.6 69.1 58.0–78.4
HPV negative 14 0.0 0.0–24.3 0.0 0.0–25.9 7.7 1.4–33.3 7.7 1.3–34.6
HPV positivee 81 65.1 53.7–75.0 66.8 55.1–76.7 68.8 57.9–77.9 72.8 62.0–81.5
Double negative 5 0.0 0.0–43.4 0.0 0.0–43.4 0.0 0.0–43.4 0.0 0.0–43.4
Cytology and/or HPV positivee 91 58.0 47.2–68.1 59.4 48.2–69.7 62.7 52.3–72.1 66.3 55.7–75.4
HPV16 50 63.7 49.6–75.8 63.7 49.1–76.2 65.3 51.3–77.1 65.3 50.8–77.4
NonHPV16 51 48.7 34.5–63.1 51.5 36.7–66.0 57.5 43.6–70.3 63.8 49.8–75.8
Abbreviations: CIN3+¼ cervical intraepithelial neoplasia grade 3 and cancer; CIN2+¼ cervical intraepithelial neoplasia grade 2, 3 and cancer; 95% CI¼ 95% confidence interval;
HPV¼ human papillomavirus. aAll women with a follow-up ofo6 months were excluded. bCytology divided into negative (normal) and positive (borderline or mild dyskaryosis
and worse). cIncluding one adenocarcinoma in situ (AIS). dIncluding one squamous cell carcinoma (SCC). eIncluding one SCC, one adenocarcinoma, and one AIS. Time to event is
set equal to histological diagnosis of CIN3+ lesion.
Long-term CIN3þ risk after HPV triage of abnormal cytology
M Kocken et al
821
British Journal of Cancer (2012) 106(5), 817 – 825& 2012 Cancer Research UK
C
li
n
ic
a
l
S
tu
d
ie
s
(95% CI 0.0–5.1), whereas a positive test result increased this risk
to 37.5% (29.0–46.9). The risks for the subsequent 5 years were
0.01% (95% CI 0.0–5.7) and 1.6% (0.2–9.5%), respectively.
Women positive for HPV16 had a higher CIN3þ risk than
women infected with other hrHPV types (Wald-statistic 5.60;
P¼ 0.02). Their 5-year risk was 49.8% (95% CI 36.2–63.4) vs 29.8%
(18.4–40.2) in women infected with other hrHPV types. The 5-year
risk remained 26.5% (95% CI 14.1–44.3) in women infected with
hrHPV types different from HPV16, 18, 31, 33 and 45.
The risk of women who tested hrHPV positive at baseline was
further stratified by follow-up testing after 6 months with either
cytology or hrHPV (Wald-statistic 8.51; P¼ 0.004 and 37.38;
Po0.0001, respectively).
After women with a follow-up shorter than 6 months had been
excluded, the CIN3þ risk of women who complied with the present
follow-up algorithm of repeat cytology testing after 6 months was
calculated. Women with normal cytology after 6 months had a 5-year
CIN3þ risk of 4.9% (95% CI 1.6–13.8), whereas women with an
abnormal test result had a risk of 30.9% (23.0–40.1). Risks in the
next 5 years were 0.01% (95% CI 0.0–7.1) and 1.4% (0.2–8.5).
After stratification for age, results for both the age groups
were statistically not different, although the risks in the younger
age group were slightly lower than in the older age group (data
not shown).
4Borderline and mild dyskaryosis
Fifty-eight of 132 (43.9%) women with baseline moderate to severe
dyskaryosis developed CIN3þ (Table 2B) and their risk was 45.1%
(95% CI 36.4–54.1) in the first 5 years and 3.5% (0.9–12.2) in
the subsequent 5 years. Also in this group immediate hrHPV
testing stratified the CIN3þ risk (Wald-statistic 12.31, P¼ 0.0005,
Figure 3B). High-risk human papillomavirus-positive women
(76.5%) had a 5-year risk of 56.6% (95% CI 46.4–66.3) and this
was 2.9% (0.5–15.4) in the subsequent 5 years. The 5-year risk for
women positive for HPV16 was similar to the risk for nonHPV16-
positive women (Wald-statistic 1.01; P¼ 0.31). Thirty-one (23.5%)
women tested hrHPV negative and had a 5-year CIN3þ risk of
7.3% (95% CI 2.0–23.6) and of 4.2% (0.6–23.2) in the subsequent
5 years. Additional testing after 6 months with either cytology,
hrHPV, or both did not further stratify the risk (Wald statistic 0.07,
P¼ 0.80; 0.02, 0.90 and 0.009, 0.93, respectively). Also after age
stratification no groups could be identified with a low enough risk
to return to routine screening.
Analyses with CIN2þ as endpoint
Results of analyses with CIN2þ as endpoint were similar to those
with CIN3þ as endpoint (Tables 1 and 2). The 5-year CIN2þ risk
for women with abnormal cytology was 38.7% (95% CI 33.6–44.1)
and this risk was 4.7% (2.4–9.0) between 5 and 10 years. Of all 141
CIN2þ lesions, 124 (87.9%) were detected in women who were
hrHPV positive at baseline. Their 5-year CIN2þ risk was 52.3%
(95% CI 45.7–58.8) and 6.1% (2.7–13.1) in the next 5 years.
Human papillomavirus 16-positive women had a 5-year CIN2þ
risk (60.0%, 95% CI 50.2–69.1) similar to the risk in women
infected with other hrHPV types (45.7%, 37.0–54.7, Wald-statistic
3.32; P¼ 0.07). Women who tested hrHPV negative at baseline had
a 5-year risk of 11.8% (95% CI 7.0–19.2) and a risk of 3.3% (1.1–
9.6) in the subsequent 5 years.
The 5-year CIN2þ risk in women with BMD was 31.0% (95% CI
25.0–37.8), and their risk in the next 5 years was 3.0% (1.1–7.8).
A negative hrHPV-test result at baseline reduced the 5-year risk to
9.9% (95% CI 5.1–18.5), whereas a positive test increased the risk
to 44.9% (37.1–52.9). Human papillomavirus 16-positive women
had a significantly higher risk than women infected with other
hrHPV types (55.3%, 95% CI 41.8–68.1 vs 38.7, 28.1–50.5).
The CIN2þ risk in women with 4BMD was 51.2% (95% CI
42.6–59.7) in the first 5 years and 8.4% (3.5–18.8) in the next 5
years. A negative hrHPV test result reduced the 5-year risk to
16.9% (95% CI 7.4–34.2) and a positive hrHPV test result
increased this risk to 61.4% (51.5–70.4%). Human papillomavirus
16 had a similar CIN2þ risk as other hrHPV types in women with
4BMD (Wald-statistic 0.01; P¼ 0.91).
DISCUSSION
This study describes the long-term cumulative risk of developing
CIN3þ after detection of abnormal cytology. For women with an
abnormal smear (XBMD) the 5-year CIN3þ risk was 31.1% and
the risk in the next 5 years was 1.6%. We stratified these risks
according to referral cytology and found that both women with
BMD and women with 4BMD referral cytology had an increased
risk of developing CIN3þ within the first 5 years after detection.
This risk was twice as high in women with4BMD compared with
women with BMD (45% vs 22%). In the subsequent 5 years only
for women with 4BMD an increased risk (3.5%) remained, while
for women referred with BMD this risk was with 0.7% similar to
that of the general population (Bulkmans et al, 2004).
Immediate hrHPV testing stratified the CIN3þ risk of women
with an abnormal smear (XBMD). Almost all CIN3þ lesions (102
out of 105), including all invasive carcinomas, were found in
women testing hrHPV positive. Almost half of all hrHPV-positive
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Figure 3 Cumulative risk curve of CIN3þ in women with (A)
borderline to mild dyskaryosis (n¼ 210) and (B) moderate to severe
dyskaryosis (n¼ 132) at baseline, according to baseline hrHPV status.
HPV-positive (continuous) women and HPV-negative (dotted) women.
Abbreviations: CIN3þ , Cervical intraepithelial neoplasia grade 3 or cancer;
hrHPV, high-risk human pappillomavirus.
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women were infected with HPV16; these women had a significantly
higher CIN3þ risk than the women infected with other hrHPV
types (Khan et al, 2005; Schiffman et al, 2005, 2011; Berkhof et al,
2006; Castle et al, 2009). This risk difference was only found in
younger women (o30 years), while in older women (X30 years)
the risks between women positive for HPV16 and women positive
for other hrHPV types were similar. This is in line with another
study (Powell et al, 2011) that found that the mean age of women
with HPV16-associated cancer was significantly lower than of
nonHPV16-associated cancer. All CIN3þ in HPV16-positive
women were identified within 5 years after detection of abnormal
cytology, while lesions associated with other hrHPV types were
also found in the 5 years hereafter. This suggests that HPV16 has
its main oncogenic effect within a shorter timeframe and at a
younger age than other hrHPV types (Safaeian et al, 2009; Powell
et al, 2011).
The CIN3þ risk was lower in women who cleared the virus than
in women with persistent hrHPV infections, with the highest risks
for women with a persistent HPV16 infection (Schiffman et al,
2005; Kjaer et al, 2006; Naucler et al, 2007; Castle et al, 2009).
Women with BMD
In correspondence with another Dutch study (Berkhof et al, 2006),
almost 25% of women with BMD developed CIN3þ . The majority
was diagnosed within the first 5 years, whereas in the subsequent
5-year period their CIN3þ risk was similar to the risk of the
general population (Bulkmans et al, 2004; Castle et al, 2007). This
implicates that women with BMD who did not develop CIN3þ
within 5 years may return to routine screening. Other studies also
found a negligible increase in high-grade CIN cases between 5 and
10 year after diagnosis of BMD cytology (Sherman et al, 2003;
Khan et al, 2005; Schiffman et al, 2011).
Meta-analyses concerning women with BMD have found that
immediate hrHPV testing better identifies women at risk of
developing CIN3þ than repeat cytology after 6 months (Arbyn
et al, 2004, 2006). Our study confirms these findings. Women with
baseline BMD and normal cytology after 6 months (31%) had a
5-year risk of 5%, while this risk was o0.1% in women with BMD
and a negative hrHPV test at baseline (40%). Therefore, we
support the referral of hrHPV-negative women with BMD to
routine screening (Castle et al, 2007; Safaeian et al, 2007; Rijkaart
et al, 2009; Katki et al, 2011; Levi et al, 2011). In both these groups,
the 5-year CIN2þ risk remained B10%. After revision, all these
lesions remained CIN2, and we believe most of them would regress
over time. However, additional testing with either cytology or
hrHPV after 6 months may be considered to minimise the risk of
CIN2.
Women with BMD who tested hrHPV positive at baseline had a
5-year CIN3þ risk of almost 40% and are in need of additional
testing and/or colposcopy (Manos et al, 1999; Bulkmans et al,
2004; Castle et al, 2007; Safaeian et al, 2007). Although hrHPV
genotyping did identify HPV16-positive women to have the highest
risk, the risk of women positive for other hrHPV types remained so
high (28%) that colposcopic referral was required, leaving hrHPV
genotyping without additional value.
Another strategy to identify women at risk for CIN3þ is hrHPV
testing after 6 months, allowing viral clearance (Bais et al, 2005;
Berkhof et al, 2005). In our study, almost half (99 out of 210) of the
women with BMD tested hrHPV negative after 6 months. As none
of them developed CIN3þ , this confirms the usefulness of this
alternative strategy. However, also with this strategy the 5-year
CIN2þ risk in hrHPV-negative women remains 10%.
Women with 4BMD
As almost half of the women with 4BMD cytology developed a
CIN3þ lesion, we support referring all women with 4BMD to
colposcopy (Bulkmans et al, 2004; Castle et al, 2007). Although
immediate hrHPV testing did stratify the risk of developing
CIN3þ , no group was identified with a risk low enough to refrain
from colposcopy. Therefore, we do not advocate hrHPV testing
in this group.
Our study has several limitations. First, the initial study
was designed such that no interference with natural history would
occur and therefore had a ‘wait and see’ period to allow the
development of real precursor lesions (CIN3), instead of transient
lesions (CIN2). When CIN2þ lesions were detected women were
treated, which is in contrast to another observational study
(McCredie et al, 2008). The waiting period is also an explanation
for the later diagnosis of CIN3þ lesions in our study than found
in a joint European cohort study in which the majority of disease
was diagnosed within 12 months (Dillner et al, 2008).
Second, our study comprises a relatively small cohort of 342
women. Although the censoring percentage at 10 years was only
20%, just one event was diagnosed after 10 years of follow-up.
Therefore, we describe the risks up to 10 years and presented
95% CI to assess all risks as precisely as possible, providing a
general impression on the long-term CIN risk of women with an
abnormal smear (XBMD). Our results corroborate and extend the
data of other (long-term) cohorts (Sherman et al, 2003; Kjaer et al,
2006; Bulk et al, 2007; Dillner et al, 2008; Katki et al, 2011;
Kelly et al, 2011; Kitchener et al, 2011; Schiffman et al, 2011). As
most CIN3þ were detected within 5 years of referral (Sherman
et al, 2003), the presented overall 5- and 10-year CIN3þ risks are
with 31.1% and 32.2% nearly similar. These risks were higher than
reported previously by Dillner (6-year risk 19%) and Sherman
(10-year risk 10.2%; 95% CI 7.6–12.9) (Sherman et al, 2003; Dillner
et al, 2008). Possible explanations include differences in the study
population, that is the relatively large proportion (39%) of women
with4BMD, and the strict endpoint of biopsy taking in the initial
study. Other studies often acted on less severe suspicions, thereby
increasing the detected number of lower grade CIN lesions
(Sherman et al, 2003; Cuzick et al, 2008; Schiffman et al, 2011).
A number of CIN2 lesions that would have been detected in
countries with less conservative referral thresholds, such as the
United States and the United Kingdom, will in the Netherlands
have developed into CIN3þ lesions before detection. This
explains the relatively higher number of CIN3þ lesions and the
relatively lower number of CIN2 lesions.
Finally, the median age was relatively low. However, conclusions
did not differ greatly after recalculating the risks for 196 women
aged X30 years (data not shown).
In conclusion, our study confirms the increased CIN3þ risk in
women with dyskaryosis. Bearing in mind the limitations of our
study, we recommend the following:
Women with BMD should receive additional hrHPV testing for
risk assessment. HrHPV-negative women may be referred to
routine screening as their 5-year CIN3þ risk is negligible.
HrHPV-positive women should be referred for additional testing
and/or colposcopy. When these women do not develop CIN3þ
within 5 years, they also may be referred to population-based
screening. Women with 4BMD should all be referred for
colposcopy and as their CIN3þ risk is elevated for at least
10 years long-term monitoring is required.
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